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Aims: Insulin glargine 300 U/mL (Gla-300) offers a flatter pharmacodynamic profile than insulin
glargine 100 U/mL (Gla-100). We have compared these insulins over 1 year in people with
type 1 diabetes (T1DM).
Methods: EDITION 4 was a 6-month, multicentre, randomized, open-label phase 3 study. Peo-
ple with T1DM who completed the 6 months continued randomized Gla-300 or Gla-100 once
daily, morning or evening, for a further 6 months.
Results: Among 549 participants randomized, 444 completed the 12-month study period
(Gla-300, 80%; Gla-100, 82%). Mean HbA1c decreased similarly from baseline to month 12 in
the 2 treatment groups (difference, 0.02 [95% CI, −0.13 to 0.17]) %-units [0.2 (−1.5 to 1.9)
mmol/mol]), to a mean of 7.86 %-units (62.4 mmol/mol) in both groups. For morning vs eve-
ning injection, there was no difference in HbA1c change over 12 months for Gla-100, but a sig-
nificantly larger decrease in HbA1c was observed in the Gla-300 morning group than in the
Gla-300 evening group (difference, −0.25 [−0.47 to −0.04] %-units [−2.7 (−5.2 to −0.4) mmol/
mol]). Mean glucose from the 8-point SMPG profiles decreased from baseline, and was similar
between the 2 treatment groups. Basal insulin dose was 20% higher with Gla-300 than with
Gla-100, while hypoglycaemia event rates, analysed at night, over 24 hours, or according to dif-
ferent glycaemic thresholds, did not differ between treatment groups, regardless of injection
time. Adverse event profiles did not differ between groups.
Conclusions: In T1DM, Gla-300 provides glucose control comparable to that of Gla-100, and
can be given at any time of day.
KEYWORDS
analogues, basal insulin, clinical trial, glycaemic control, hypoglycaemia, insulin, type
1 diabetes
1 | INTRODUCTION
In people with type 1 diabetes (T1DM), long-term maintenance of
blood glucose levels close to normal is associated with a reduction in
progression of microvascular complications and in all-cause mortal-
ity.1,2 Current guidelines recommend insulin analogues for people
with T1DM, because of the lower associated risk of hypoglycaemia
compared with optimized insulin therapy with human insulin.3
Nevertheless, blood glucose control remains suboptimal in many
people,4,5 with described barriers including concerns about hypogly-
caemia, flexibility of injection schedule and weight gain.5 Some of
these difficulties may be related to action profiles of conventional
extended-acting insulins and the first-generation long-acting insulin
analogues.5,6
In people with type 2 diabetes (T2DM) already receiving insulin,
the more stable and prolonged pharmacokinetic and pharmacodynamic
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profiles of insulin glargine 300 U/mL (Gla-300) vs those of glargine
100 U/mL (Gla-100)7 translate into sustained glycaemic control for
1 year, with less nocturnal hypoglycaemia.8,9 In T1DM in the EDI-
TION 4 clinical trial, 549 people were randomized to Gla-300 or
Gla-100 as basal insulin, and to morning or evening injection.10 The
primary 6-month results showed equivalent glycaemic control and a
lower risk of nocturnal hypoglycaemia with Gla-300 vs Gla-100 dur-
ing the first 8 weeks.10 Glucose profiles, rates of hypoglycaemia and
adverse events were comparable, irrespective of morning or evening
Gla-300 injection,10 suggesting that Gla-300 provides the freedom to
choose a morning or evening injection schedule without compromis-
ing glycaemic control or increasing hypoglycaemia. In the current 6-
month, pre-planned continuation of EDITION 4, we investigated the
safety, tolerability and efficacy of Gla-300 compared with Gla-100,
given morning or evening, over 12 months.
2 | MATERIALS AND METHODS
2.1 | Study design and participants
EDITION 4 was a multicentre, 4-arm, parallel-group, phase 3a study
in people with T1DM who were randomized (1:1:1:1) to once-daily
Gla-300 or Gla-100 (both Sanofi, Paris, France), injected morning or
evening, while continuing meal-time insulin (NCT01683266).10 Peo-
ple completing the 6-month main study period continued open-label
Gla-300 or Gla-100 once daily in the morning or evening, as previ-
ously randomized, for a further 6 months. The EDITION 4 study
design was reported in detail in the primary 6-month report.10
Participants were aged ≥18 years, had T1DM for >1 year, had
HbA1c in the range of 7.0 %-units to 10.0 %-units (53 to 86 mmol/mol)
and had spent >1 year on basal insulin combined with a meal-time insu-
lin analogue. Gla-300 was given subcutaneously using a modified Tacti-
Pen pen-injector (Sanofi) that allowed 1.5 U dose increments, while
Gla-100 was given subcutaneously using the SoloSTAR pen (Sanofi),
allowing 1 U dose increments.
Basal insulin was titrated to a pre-breakfast self-monitored
plasma glucose (SMPG) level of 4.4 to 7.2 mmol/L (80–130 mg/dL).10
Dose adjustments of basal insulin were made weekly, and no more
often than every 3 to 4 days.10 Meal-time insulin was continued with
a target range of <8.9 mmol/L (160 mg/dL) for 2-hour postprandial
plasma glucose, adjusted at investigator/participant discretion.10
The study was approved by relevant review boards/ethics com-
mittees, and was performed in accordance with the Declaration of
Helsinki and the International Conference on Harmonization guide-
lines. All participants provided written informed consent.10
2.2 | Outcomes
Efficacy outcomes included change from baseline to month 12 in
HbA1c, central-laboratory-measured fasting plasma glucose (FPG),
pre-breakfast SMPG, 8-point SMPG profiles and insulin dose (basal
and meal-time).
Hypoglycaemia assessments included the percentage of partici-
pants reporting ≥1 event and event rates. Events were categorized
using American Diabetes Association (ADA) definitions11: “severe”
hypoglycaemia was defined as an event that required assistance;
“documented symptomatic” hypoglycaemia required typical symp-
toms with a plasma glucose concentration ≤3.9 mmol/L (≤70 mg/dL);
“confirmed or severe” hypoglycaemia included symptomatic or
asymptomatic events with plasma glucose concentration ≤3.9
mmol/L (≤70 mg/dL) and “severe” events. A pre-planned sensitivity
analysis using <3.0 mmol/L (<54 mg/dL) was done. “Night-time” was
defined as 0:00 to 5:59 AM.
Treatment-emergent adverse events (AEs) and body weight were
systematically recorded at each visit. Participant-reported satisfaction
with treatment and perception of occurrence of hypo- and hyper-
glycaemia were assessed using the Diabetes Treatment Satisfaction
Questionnaire (status) (DTSQs), and health-related quality of life was
assessed with the EQ-5D questionnaire.12,13 Behaviours and worries
related to hypoglycaemia were assessed with the Hypoglycaemia
Fear Survey-II (HFS II).14
2.3 | Data analysis and statistics
Efficacy analyses were based on the modified intention-to-treat
(mITT) population, defined as all randomized participants who
received ≥1 dose of study insulin and had a baseline and at least one
post-baseline efficacy assessment. Continuous endpoints were ana-
lysed using a mixed model for repeated measures (MMRM) approach,
and categorical variables were analysed using a Cochran–Mantel–
Haenszel (CMH) method.10
Hypoglycaemia and safety analyses were based on the safety
population: all participants randomized and receiving ≥1 treatment
dose. Change in body weight was assessed using an analysis of covar-
iance (ANCOVA) model. Calculation of rate ratio for hypoglycaemic
event rate was done using an over-dispersed Poisson regression
model. AEs were coded using the Medical Dictionary for Regulatory
Activities (MedDRA) version 17.0.
3 | RESULTS
3.1 | Participants
All 549 people with T1DM who were randomized to Gla-300
(n = 274) or Gla-100 (n = 275) received study insulin (the safety pop-
ulation) (Figure S1). All participants randomized to Gla-300 met cri-
teria for the mITT population (above), but there was no baseline or
post-baseline efficacy data for 2 Gla-100 participants (n = 273 mITT
participants). In the Gla-300 group, 136 and 138 participants received
morning and evening injections, respectively, and in the Gla-100
group, 135 and 138 participants received morning and evening injec-
tions, respectively.
The 12-month study period was completed by 219 participants
(80%) in the Gla-300 group and by 225 (82%) in the Gla-100 group
(Figure S1). Most discontinuations occurred in the first 6 months of
the study (Gla-300, 43; Gla-100, 39), with few during the second
6 months (Gla-300, 12; Gla-100, 11). The most common explanation
given for treatment discontinuation was “other reasons” (32 [12%]
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and 38 [14%] participants in the 2 groups, respectively), usually stat-
ing personal/family or job-conflict reasons (17 and 25 participants,
respectively).
Baseline characteristics have been fully described previously.10
Mean (SD) age of participants was 47.3 (13.7) years; 57% were male;
BMI was 27.6 (5.1) kg/m2; and body weight was 81.8 (18.7) kg. Dura-
tion of T1DM was 21.0 (12.9) years and most participants (82%)
transferred from insulin glargine. Baseline HbA1c was 8.13 (0.8)
%-units (65.3 [9] mmol/mol) and laboratory-measured clinic FPG was
10.7 (4.4) mmol/L (193 [79] mg/dL). No notable differences in base-
line characteristics were observed between the insulin groups or in
morning vs evening injection.
3.2 | Insulin dose
Mean (SD) daily basal insulin dose prior to the study was 0.38
(0.17) U/kg (32.3 [20.8] U) in the Gla-300 group and 0.37 (0.15) U/kg
(30.6 [15.2] U) in the Gla-100 group. These doses were lower at day
1 (“baseline”) (Table S1) and then increased to month 12 in both
groups (Gla-300 to 0.48 [0.22] U/kg; Gla-100 to 0.40 [0.18] U/kg),
mostly during the first 8 weeks (Figure 1A). The meal-time total insu-
lin dose remained stable in both groups throughout the study.
Mean daily basal insulin doses at 12 months in the Gla-300
group were 0.51 (0.23) U/kg for morning injections and 0.46
(0.21) U/kg for evening injections; corresponding doses in the
Gla-100 group were 0.45 (0.18) U/kg and 0.36 (0.17) U/kg
(Table S1). Total daily insulin dose at month 12 for morning injections
was 15.6% higher in the Gla-300 group (0.87 [0.33] U/kg) than in the
Gla-100 group (0.75 [0.25] U/kg), and for evening injections it was
16.8% higher (0.82 [0.36] vs 0.70 [0.28] U/kg). At month 12, while
basal insulin was 58.2% of total dose with Gla-300 and, similarly,
59.5% with Gla-100 in the morning injection groups, these propor-
tions were 56.1% and 51.7% in the evening groups.
3.3 | Blood glucose control
Mean HbA1c decreased similarly from baseline to month 12 in the
Gla-300 and Gla-100 groups (Figure 1C and Table 1). LS mean differ-
ence in change from baseline (Gla-300 vs Gla-100) was 0.02 (95% CI,
−0.13 to 0.17) %-units (0.2 [95% CI,−1.5 to 1.9] mmol/mol), with
most of the decrease by week 12. During the second 6-month period,
mean HbA1c increased similarly in the 2 groups, remaining below
baseline and ending at 7.86 (SD, 1.03) %-units (62.4 [SD, 11.3] mmol/
mol) and 7.86 (SD, 0.84) %-units (62.4 [SD, 9.2] mmol/mol) in the
Gla-300 and Gla-100 groups, respectively (Figure 1C). When compar-
ing morning and evening injection (Figure 1D), there was no differ-
ence in HbA1c change over 12 months for the Gla-100 group, but a
significantly larger decrease was observed in the Gla-300 morning
group (ending at 7.76 [SD, 0.98] %-units [61.4 (SD, 10.7) mmol/mol])
than in the Gla-300 evening group (ending at 7.96 [SD, 1.07] %-units
[63.5 (SD, 11.7) mmol/mol]) (LS mean difference [95% CI] in change
from baseline, −0.25 [−0.47 to −0.04] %-units (−2.7 [−5.2 to −0.4]
mmol/mol).
A comparable reduction in laboratory-measured clinic FPG from
baseline to month 12 was seen with Gla-300 and Gla-100 (Figure 1E
and Table 1). LS mean difference in change from baseline to month
12 was 0.18 (95% CI, −0.55 to 0.90) mmol/L (3.2 [−10.0 to
16.3] mg/dL). No effect of injection time was observed for the time
course of laboratory-measured FPG, with comparable reductions by
month 12 for evening and morning groups (Figure 1F).
By month 12, plasma glucose levels on 8-point SMPG profiles
had decreased at all time points compared with baseline, and were
comparable between the insulin groups, except at bedtime, with
lower levels in the Gla-300 group than in the Gla-100 group
(Figure 1G). At month 12, 8-point SMPG profiles were comparable
between morning and evening injection groups for Gla-300 and
Gla-100 (Figure 1H), except pre-breakfast, which was lower for eve-
ning injections than for morning injections with Gla-300.
3.4 | Hypoglycaemia
Over 12 months nearly all participants (260 [~95%] in each group)
experienced ≥1 confirmed (≤3.9 mmol/L [≤70 mg/dL]) or severe hypo-
glycaemic event (risk ratio, 1.00 [0.96–1.05]); most participants
(199 [73%] for Gla-300 and 205 [75%] for Gla-100) experienced ≥1
nocturnal event (risk ratio, 0.97 [0.88–1.08]) (Table 2). Annualized rates
of confirmed or severe hypoglycaemia were 75.9 events/person-year
in the Gla-300 group and 68.8 events/person-year in the Gla-100
group at any time of day (24 hours) (rate ratio, 1.11 [0.97–1.29]), and
8.1 and 8.6 events/person-year at night (rate ratio, 0.95 [0.75-1.20])
(Table 2). Cumulative mean events over time are given in Figure 2A,B.
No trends with time are seen for nocturnal hypoglycaemia, but there
were numerically more events at any time of day (24 hours) in the sec-
ond 6-month period with Gla-300 compared with Gla-100.
In the sensitivity analysis with a confirmation threshold of
<3.0 mmol/L (<54 mg/dL), risk of hypoglycaemia and rate ratios
remained statistically non-significant (Table 2). Similar patterns were
observed using a definition of documented symptomatic hypoglycae-
mia, at either plasma glucose threshold (Table 2). When hypoglycae-
mia rates were compared for the morning and evening groups
statistical power was lower; thus, the central estimates were more
erratic and confidence intervals were wider (Table S2). There were no
statistically significant differences in any category of confirmed hypo-
glycaemia or documented symptomatic hypoglycaemia between
study insulins.
At least 1 severe hypoglycaemic event at any time of day was
reported by 25 (9%) participants in the Gla-300 group and by
31 (11%) participants in the Gla-100 group. Among these, 9 (3%) in
each group experienced nocturnal events (Table 2). Annualized rates
(events/person-year) of severe hypoglycaemia were 0.37 for Gla-300
and 0.24 for Gla-100 at any time of day (24 hours), and 0.08 and
0.05, respectively, during the night. Confidence intervals for study
prevalence and event rates were very wide (Table 2 and Table S2).
3.5 | Body weight
Body weight increased in both treatment groups, but the statistically
significant difference at 6 months in favour of Gla-30010 was lost at
12 months (LS mean difference [95% CI] in change from baseline to
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month 12 [last on-treatment value], −0.5 [−1.1 to 0.1] kg [P = .098])
(Figure 1B).
3.6 | Participant-reported outcomes
Mean change in total DTSQs scores from baseline to month 12 was
similar in the 2 groups (Gla-300, 1.3 [SD, 5.3]; Gla-100, 1.6 [SD, 4.9])
(Table S3). Health status measured with EQ-5D showed no change
over 12 months in either group (Table S3). For HFS II scores, mean
change from baseline to month 12 in total HFS II score was small and
similar between groups (Gla-300, −0.02 [SD, 0.40]; Gla-100, −0.02
[SD, 0.43]) (Table S3).
3.7 | Adverse events and insulin antibodies
The number of participants who reported an AE during the 12-month
treatment period was similar in the Gla-300 (198 [72%]) and Gla-100
(187 [68%]) groups, as was the pattern of AEs. Serious AEs were
reported by 27 (10%) Gla-300 participants and 26 (10%) Gla-100 par-
ticipants, without a notable difference for any type of event. One
participant in the Gla-300 group, with pre-existing cardiovascular dis-
ease, died of a cardiac event during the first 6-month period.10 Five
participants in the Gla-300 group and 4 in the Gla-100 group with-
drew from the study because of AEs. Injection site reactions, none
serious or resulting in treatment discontinuation, were reported in
8 participants (2.9%) in the Gla-300 group and 4 participants (1.5%)
in the Gla-100 group.
Throughout the 12-month on-treatment period, the percentage
of participants who were positive at any time for anti-insulin antibo-
dies was comparable between the Gla-300 (89% [237/266]) and the
Gla-100 (87% [235/270]) groups. The percentage of participants who
were negative for anti-insulin antibodies at baseline, but positive
later, was also comparable (74% [72/97] and 74% [90/122],
respectively).
4 | DISCUSSION
Here we report on the 12-month period of observation for the
EDITION 4 study. This nearly doubles the exposure of people with
T1DM to Gla-300 as compared to the 6-month data,10 while main-
taining the primary randomization, both vs Gla-100 and between
morning and evening injections in both treatment groups. The report
thus includes considerably more tolerability and safety data than did
the primary 6-month study.10 The extension-period data have also
helped to identify longer-term trends in glucose control, and allow
hypoglycaemia rates that are less influenced by distortions in the
period after randomization that resulted from beginning a new insulin
treatment with which the investigators and participants had no prior
experience.
In the equivalent basal and meal-time insulin study in T2DM,
EDITION 1, evolution of blood glucose control in the second
6-month period showed a small but statistically significant advantage
of Gla-300 in change in HbA1c from baseline at 12 months.8 In
EDITION 4, the change from baseline in HbA1c observed at
6 months remained comparable between Gla-300 and Gla-100
throughout the 12-month study period (Figure 1C and Table 1). This
finding is in line with that observed at 12 months in the basal and
meal-time insulin study in T1DM conducted in Japan, EDITION JP
1.15 However, for HbA1c in the morning vs evening injection groups
in EDITION 4, which for Gla-100 was comparable both at 6 and
12 months, for Gla-300 there was a significantly larger decrease in
favour of the morning group (Figure 1D). It should be noted that the
morning injection groups used higher (basal and total) insulin doses
than the evening injection groups, for both Gla-300 and Gla-100. The
reason for this is not clear, and comparison of morning and evening
injection schedules (a specified objective secondary to the overall
comparison of the 2 insulins) is complicated by diurnal hormonal
changes and differences in patterns of physical activity. Meal-time
insulin use may also be a contributing factor, although in this study
very little titration of meal-time insulin dose occurred. Of interest, a
study in T1DM using continuous glucose monitoring (CGM) showed
that Gla-300 24-hour glucose profiles did not differ, irrespective of
basal insulin being administered in the morning or evening16; a large
ongoing study using CGM to investigate Gla-300 and Gla-100 given
in the morning may provide further insights.17 The findings presented
here highlight the value of longer-term studies.
TABLE 1 Glycaemic control measures over 12 months of treatment
with Gla-300 or Gla-100
Gla-300 Gla-100
HbA1c (%)
Baseline 8.13 (0.77) 8.12 (0.79)
Month 12 7.86 (1.03) 7.86 (0.84)
Change −0.20 (0.06) −0.22 (0.06)
LS mean difference (95% CI) 0.02 (−0.13 to 0.17)
HbA1c (mmol/mol)
Baseline 65.3 (8.4) 65.2 (8.6)
Month 12 62.4 (11.3) 62.4 (9.2)
Change −2.2 (0.6) −2.4 (0.6)
LS mean difference (95% CI) 0.2 (−1.5 to 1.9)
FPG (mmol/L)
Baseline 10.26 (4.14) 11.02 (4.46)
Month 12 9.79 (3.87) 9.63 (3.62)
Change −0.43 (5.22) −1.39 (5.43)
LS mean difference (95% CI) 0.18 (−0.55 to 0.90)
Average 24-h SMPG (mmol/L)
Baseline 9.40 (2.54) 9.60 (2.34)
Month 12 9.02 (2.23) 8.99 (2.22)
Change −0.36 (2.77) −0.58 (2.87)
LS mean difference (95% CI) 0.12 (−0.34 to 0.58)
Pre-breakfast SMPG (mmol/L)
Baseline 8.91 (2.56) 9.28 (2.51)
Month 12 8.44 (2.29) 8.40 (2.09)
Change −0.32 (2.98) −0.76 (2.71)
Abbreviations: FPG, laboratory-measured clinic fasting plasma glucose;
mITT, modified intention-to-treat; SD, standard deviation; SMPG, self-
monitored plasma glucose.
mITT population. Data are presented as mean (SD) unless otherwise
mentioned.
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The 12-month data from EDITION 4 showed that change in
laboratory-measured clinic FPG was comparable between the Gla-
300 and Gla-100 groups. This measure, however, is not relevant to
clinical practice as it requires people with T1DM to delay breakfast
and breakfast insulin, something they are advised to avoid absolutely.
Unfortunately, findings from the SMPG profiles are also unclear, in
part because of baseline differences between the 2 treatment groups
for the 3:00 AM and pre-breakfast glucose levels. However, endpoint
findings at these times are similar (Figure 1G). There is some sugges-
tion of separation between the Gla-300 and Gla-100 month-12
SMPG profiles in the evening (bedtime) (Figure 1G), and this would
seem to be confirmed by the data in Figure 1H, where SMPG profiles
at 12 months for morning and evening injection are given. No separa-
tion of the 2 insulins at bedtime is seen for morning injection, while a
separation can be perceived for evening injections in favour of
Gla-300. Speculatively, such a separation between insulins could be
related to a failure of Gla-100 to provide insulinization as effective as
that of Gla-300 in the hours immediately before the next injection,
consistent with the comparative pharmacodynamic clamp data.7 As a
caution, it should be noted that statistical testing of individual self-
monitored time points was not in the pre-determined analysis plan,
and profile interpretations are a matter of observation only.
The difficulty in interpreting morning and evening profiles illus-
trates a study limitation, namely, that the double comparison (two
insulins, and morning versus evening) results in relatively small indi-
vidual populations (~140 people); consequently, each show relatively
variable glucose profiles (Figure 1), particularly for laboratory-
measured clinic FPG and SMPG profiles. That said, for Gla-300,
which is expected from pharmacokinetic and pharmacodynamic stud-
ies, and notably from a CGM study, to be a true ≥24-hour
insulin,7,16,18 there should be no difference in glucose-related out-
comes between morning and evening. Any trend in morning injection
control being better than that with evening injections could be
explained by the higher dose used by the morning group.
Hypoglycaemia risks and rates did not differ between the 2 study
insulins in any of the measures analysed (nocturnal/any time of day,
confirmed or severe/documented symptomatic, thresholds of ≤3.9 or
<3.0 mmol/L, severe alone) (Table 2). However, as is usual in this
type of trial, EDITION 4 was not powered to detect differences in
hypoglycaemia. Numerical differences in anytime (24 hours) severe
hypoglycaemia event rates, which do not approach statistical signifi-
cance, can be explained by the fact that 1 participant in the Gla-300
group reported 42 severe daytime events during the extension
period. Cumulative event curves support the rate ratio data in reveal-
ing no differences between Gla-300 and Gla-100, but there is a trend
to divergence of anytime events in the second 6-month period, which
needs further study (Figure 2). These findings differ from those of the
EDITION JP 1 study, which investigated evening basal insulin
TABLE 2 Population experiencing hypoglycaemia and event rates over 12 months
Nocturnal hypoglycaemia (00:00–05:59 h) Hypoglycaemia at any time (24 h)
Gla-300
(n = 274)
Gla-100
(n = 275) RR 95% CI
Gla-300
(n = 274)
Gla-100
(n = 275) RR 95% CI
Total person-years 237.5 242.2 237.5 242.2
Confirmed or
severe
hypoglycaemia
≤3.9 mmol/L
(≤70 mg/dL)
Participants,
n (%)
199 (72.6) 205 (74.5) 0.97 0.88–1.08 260 (94.9) 260 (94.5) 1.00 0.96–1.05
Events, n (per
person-year)
1917 (8.1) 2079 (8.6) 0.95 0.75–1.20 18 018 (75.9) 16 661 (68.8) 1.11 0.97–1.29
<3.0 mmol/L
(<54 mg/dL)
Participants,
n (%)
151 (55.1) 162 (58.9) 0.94 0.81–1.08 225 (82.1) 231 (84.0) 0.98 0.91–1.06
Events, n (per
person-year)
658 (2.8) 750 (3.1) 0.90 0.68–1.20 4372 (18.4) 4068 (16.8) 1.11 0.91–1.35
Documented
symptomatic
hypoglycaemia
≤3.9 mmol/L
(≤70 mg/dL)
Participants,
n (%)
176 (64.2) 174 (63.3) 1.01 0.89–1.15 240 (87.6) 238 (86.5) 1.01 0.95–1.08
Events, n (per
person-year)
1228 (5.2) 1379 (5.7) 0.91 0.69–1.21 9286 (39.1) 8490 (35.1) 1.12 0.92–1.37
<3.0 mmol/L
(<54 mg/dL)
Participants,
n (%)
133 (48.5) 134 (48.7) 1.00 0.84–1.18 202 (73.7) 206 (74.9) 0.98 0.89–1.09
Events, n (per
person-year)
472 (2.0) 574 (2.4) 0.85 0.61–1.18 2522 (10.6) 2559 (10.6) 1.01 0.80–1.28
Severe
hypoglycaemia
Participants,
n (%)
9 (3.3) 9 (3.3) 1.01 0.44–2.28 25 (9.1) 31 (11.3) 0.81 0.50–1.33
Events, n (per
person-year)
18 (0.08) 11 (0.05) 1.57 0.49–5.04 87 (0.37) 57 (0.24) 1.61 0.57–4.58
Abbreviations: CI, confidence interval; RR, risk ratio for percentage of participants with ≥1 event, or rate ratio for events per person-year.
Safety population.
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injections; in that study Gla-300 was associated with a lower risk and
rate of nocturnal (0:00–05:59 AM) confirmed (<3.0 mmol/L [<54 mg/
dL]) or severe hypoglycaemia vs Gla-100.15 They also differ from
results with another long-acting insulin (insulin degludec) in T1DM
when given as an evening injection, which show lower rates of noc-
turnal hypoglycaemia with insulin degludec vs Gla-100.19,20 However,
of note, a trial-level meta-analysis of degludec and Gla-100 in T2DM
suggests less reduction in HbA1c with degludec.21 When Gla-300 is
used in T2DM, an advantage over Gla-100 was found, both in the
basal plus meal-time study to 1 year,8 and in the patient-level meta-
analysis of 3 international studies in T2DM.22 In both the present
study and the degludec studies, nocturnal hypoglycaemia rates
remain clinically important even with the new insulins, emphasizing
that flat true ≥24-hour insulin profiles still suffer from lack of the
minute-to-minute control of insulin delivery that is needed physiolog-
ically to eliminate the risk of hypoglycaemia.23
Reported AEs over 12 months were similar in the 2 groups; most
would be background noise.10,24 Data concerning serious AEs,
whether overall or when analysed by organ and term (data not
shown), did not reveal any signal of concern, and injection site reac-
tions did not differ between treatment groups. As noted previously,10
the circulating active metabolite of glargine is the same for Gla-300
as for the familiar and much-tested Gla-100.
The study limitations are generally inherent to clinical studies of
this kind in people with T1DM. Confounding of glucose control and,
particularly, hypoglycaemia may occur through the use and titration
of meal-time insulins, and while doses of these did not differ between
treatment groups at 6 months, they were slightly different at
12 months (Figure 1A). This is relevant, as the majority of hypogly-
caemic events occurred during the day rather than at night (Table 2
and Figure 2). HbA1c reduction was less in this study than that seen
in a study of insulin degludec.20 It is not clear if this is related to the
population studied or the insulin dose titration, but it may have lim-
ited statistical power to show differences in hypoglycaemia event
rates. In addition, the discontinuation rate in this study was higher
than is desirable, although this was matched between the Gla-300
and Gla-100 groups. While our study groups are perhaps typical of a
modern T1DM population, the relatively high mean age and BMI, and
the total insulin dose, may mean that the results are less generalizable
to younger or leaner people.
In conclusion, at 12 months the results of the EDITION 4 clinical
trial suggest that, in people with T1DM of long duration studied in a
range of countries, Gla-300 has glucose control properties similar to
those of Gla-100, albeit with a somewhat higher dose requirement.
There was no evidence of new tolerability or safety issues over the
12 months of exposure. Comparison between morning and evening
injection suggests little difference in glucose profiles and no differ-
ence in hypoglycaemia or AEs for Gla-300, consistent with pharmaco-
kinetic/pharmacodynamic data. These findings imply that the timing
of Gla-300 injection can be flexible, allowing injection at any time of
day. More complete assessment of glucose profiles provided by the
use of CGM may better determine the relative benefits of Gla-300
over Gla-100, and facilitate better management of meal-time insulin
in the context of a more stable basal insulin effect. Furthermore,
studies in routine clinical practice may help evaluate the advantage to
users of morning rather than evening injection of the basal insulin.
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FIGURE 2 Cumulative mean number of confirmed (≤3.9 mmol/L
[≤70 mg/dL]) or severe hypoglycaemic events per participant during
12 months of treatment with Gla-300 or Gla-100: A, events at any
time of day (24 hours) and B, nocturnal events. Safety population
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